Fig. 1From: Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE studyFlowchart of subject enrollment. A total of 175 patients were enrolled and randomized to ipragliflozin or sitagliptin. Of the 175 participants, 15 were excluded from the efficacy analysis due to protocol violations, no baseline measurements, withdrawal of informed consent, and no follow-up measurements. I.C., informed consentBack to article page